Alethia Biotherapeutics to be part of the World ADC San Diego 2014.
Dr. Gilles Tremblay will be in attendance.
October 8 – 9, 2014
Alethia Biotherapeutics to present at the 12th Annual Discovery on Target conference at the Westin Boston Waterfront, Boston, MA. Dr. Mario Filion, Chief Scientific Officer, will be a speaker during the Antibodies Against Membrane Protein Targets session on October 9: “Targeting Siglec-15 for Therapeutic Inhibition of Osteoclastic Bone Resorption Results in the Maintenance of Bone Formation”.
September 12 – 15, 2014
Alethia Biotherapeutics to be part of the ASBMR Annual Meeting at the George R. Brown Convention Center, Houton, Texas.
Drs. Anna Moriatis and Gilles Tremblay will be in attendance.
May 30 – June 3, 2014
Alethia Biotherapeutics to be part of the ASCO Annual Meeting at the McCormick Place, Chicago, Illinois.
Drs. Mario Filion and Gilles Tremblay will be in attendance.
April 5 – 9, 2014
Alethia Biotherapeutics to present at the AACR Annual Meeting 2014 at the San Diego Convention Center, San Diego, California. Drs. Mario Filion and Gilles Tremblay will present data on:
AB-3A4: A novel KAAG1-targeting antibody-drug conjugate is active in models of ovarian carcinoma, triple-negative breast cancer and castration-resistant prostate cancer. Abstract #666. Sunday, Apr 06, 2014, 1:00 PM – 5:00 PM; Hall A-E, Poster Section 28
January 13 -16, 2014
Alethia Biotherapeutics to be part of the Biotech Showcase 2014, Parc 55 Windham Hotel, San Francisco, USA. Yves Cornellier and Mario Filion will be in attendance.